Needham Reiterates Buy on Harmony Biosciences Hldgs, Maintains $50 Price Target

Benzinga · 2d ago
Needham analyst Ami Fadia reiterates Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Buy and maintains $50 price target.